The inhibiting effect of the Coptis chinensis polysaccharide on the type II diabetic mice

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 111-119

  Cui, Lijuan ^a,b   Liu, Min ^b   Chang, XiangYun ^b   Sun, Kan ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHIHEZI UNIVERSITY   (China)

Author keywords

Coptis chinensis polysaccharide; Diabetes; Glucose tolerance; High fat diet; Hyperglycemia

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ANTIDIABETIC AGENT; CHOLESTEROL; COPTIS CHINENSIS POLYSACCHARIDE; GLUCAGON; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN; INTERLEUKIN 6; NICOTINAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; POLYSACCHARIDE; RAPAMYCIN; ROSIGLITAZONE; SIRTUIN 1; SIRTUIN 4; SIRTUIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2-(N-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)AMINO)-2-DEOXYGLUCOSE; 4 CHLORO 7 NITROBENZOFURAZAN; ADIPOCYTOKINE; CYTOKINE; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL; LIPID;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COPTIS CHINENSIS; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLUCAGON RELEASE; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE OXIDATION; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; LANGERHANS CELL; MOUSE; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CHEMISTRY; COPTIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; GLUCONEOGENESIS; LIPID DIET; MALE; METABOLISM; PHOSPHORYLATION;

3T3-L1 CELLS; 4-CHLORO-7-NITROBENZOFURAZAN; ADENYLATE KINASE; ADIPOCYTES; ADIPOKINES; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; COPTIS; CYTOKINES; DEOXYGLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FASTING; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; INSULIN; LIPIDS; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; POLYSACCHARIDES;

EID: 84962856344     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.03.038     Document Type: Article

References (33)

1. Tahrani A.A., Piya M.K., Kennedy A., Barnett A.H. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol. Ther. 2010, 125:328-361.
2. Miller R.A., Chu Q., Xie J., Foretz M., Viollet B., Birnbaum M.J. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013, 494:256-260.
3. Lee T.I., Chen Y.C., Kao Y.H., Hsiao F.C., Lin Y.K., Chen Y.J. Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration. Int. J. Cardiol. 2011, 165:299-307.
4. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414:821-827.
5. Liu Q., Chen L., Hu L., Guo Y., Shen X. Small molecules from natural sources, targeting signaling pathways in diabetes. Biochim. Biophys. Acta 2010, 1799:854-865.
6. Prieto J.M., Recio M.C., Giner R.M. Influence of traditional Chinese anti-inflammatory medicinal plants on leukocyte and platelet functions. J. Pharm. Pharmacol. Ther. 2003, 55:1257-1282.
7. Yuan L.J., Tu D.W., Ye X.L. Hypoglycemic and hypocholesterolemic effects of Coptis chinensis franch inflorescence. Plant Foods Hum. Nutr. 2006, 61:139-144.
8. Wang H., Zhang F., Ye F. The effect of Coptis chinensis on the signaling network in the squamous carcinoma cells. Front. Biosci. 2011, 1:326-340.
9. Fu Y., Hu B.R., Tang Q. Effect of jatrorrhizine, berberine, huanglian decoction and compound-mimic prescription on blood glucose in mice. Chin. Tradit. Herb. Drugs 2005, 36:548-551.
10. Zheng Z., Chang B., Li M. Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats. Am. J. Chin. Med. 2011, 39:53-63.
11. Li J.C., Meng X.L., Fan X.J. Pharmacodyamic material basis of Rhizoma Coptidis on insulin resistance. China J. Chin. Mater. Med. 2010, 35:1855-1858.
12. Jung D.W., Ha H.H., Zheng X., Chang Y.T., Williams D.R. Novel use of fluorescent glucose analogues to identify a new class of triazine-based insulin mimetics possessing useful secondary effects. Mol. Biosyst. 2011, 2:346-358.
13. Lottenberg A.M., Afonso M.S., Lavrador M.S., Machado R.M., Nakandakare E.R. The role of dietary fatty acids in the pathology of metabolic syndrome. J. Nutr. Biochem. 2012, 23:1027-1040.
14. Kwon H., Pessin J.E. Adipokines mediate inflammation and insulin resistance. Front. Endocrinol. 2013, 4:71.
15. Okamoto Y., Kihara S., Funahashi T., Matsuzawa Y., Adiponectin Libby P. A key adipocytokine in metabolic syndrome. Clin. Sci. 2006, 110:267-278.
16. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 2005, 26:439-451.
17. Tschop M., Heiman M.L. Rodent obesity models: an overview. Exp. Clin. Endocrinol. Diabetes 2001, 109:307-319.
18. Lin S., Thomas T.C., Storlien L.H., Huang X.F. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int. J. Obes. Relat. Metab. Disord. 2000, 24:639-646.
19. Raucci R., Rusolo F., Sharma A., Colonna G., Castello G., Costantini S. Functional and structural features of adipokine family. Cytokine 2013, 61:1-14.
20. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006, 17:4-12.
21. Omar B., Pacini G., Ahren B. Differential development of glucose intolerance and pancreatic islet adaptation in multiple diet induced obesity models. Nutrients 2012, 4:1367-1381.
22. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
23. Canto C., Gerhart-Hines Z., Feige J.N., Lagouge M., Noriega L., Milne J.C., et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
24. Schug T., Li X. Sirtuin 1 in lipid metabolism and obesity. Ann. Med. 2011, 43:198-211.
25. Zhang W.Y., Lee J.J., Kim I.S., Kim Y., Park J.S., Myung C.S. 7-O-methylaromadendrin stimulates glucose uptake and improves insulin resistance in vitro. Biol. Pharm. Bull. 2010, 33:1494-1499.
26. Huang S., Czech M.P. The GLUT4 glucose transporter. Cell Metab. 2007, 5:237-252.
27. Steinberg G.R., Kemp B.E. AMPK in health and disease. Physiol. Rev. 2009, 89:1025-1078.
28. Zhang B.B., Zhou G., Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009, 9:407-416.
29. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3329-3335.
30. Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R., Witters L.A. The Ca2+/Calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 2005, 280:29060-29066.
31. Anderson K.A., Means R.L., Huang Q.H., Kemp B.E., Goldstein E.G., Selbert M.A., et al. Components of a calmodulin-dependent protein kinase cascade Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase β. J. Biol. Chem. 1998, 273:31880-31889.
32. Anderson K.A., Ribar T.J., Lin F., Noeldner P.K., Green M.F., Muehlbauer M.J., et al. Hypothalamic CaMKK2Contributes to the regulation of energy balance. Cell Metab. 2008, 7:377-388.
33. Witters L.A., Kemp B.E., Means A.R. Chutes and Ladders The search for protein kinases that act on AMPK. Trends Biochem. Sci. 2006, 31. 13-6.